MedPage Today -- Adding cisplatin to standard gemcitabine (Gemzar) extended survival in biliary tract cancer without added toxicity in a phase III clinical trial, researchers said.
MedPage Today -- Adding cisplatin to standard gemcitabine (Gemzar) extended survival in biliary tract cancer without added toxicity in a phase III clinical trial, researchers said.